- Conditions
- HIV-1-infection
- Interventions
- Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 88
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,578 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2020
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Interventions
- Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
- Interventions
- revumenib, cobicistat
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 30 Days and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 22
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 17 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- NNRTI, FTC/TDF, Stribild
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- Stribild
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
- Conditions
- HIV-1 Infection
- Interventions
- F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more
- Conditions
- HIV-1 Infection
- Interventions
- B/F/TAF, NRTIs, Third Agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- E/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 30 more
- Conditions
- HIV-1-Infection
- Interventions
- ISL/LEN, Antiretroviral Combinations
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more
- Conditions
- HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
- Interventions
- Switch to E/C/FTC/TAF daily
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- COBI, DRV, NRTIs
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more
- Conditions
- HIV in Adults
- Interventions
- Atazanavir, Cobicistat, Active Pharmaceutical Ingredient
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Woburn, Massachusetts
- Conditions
- Healthy Volunteers
- Interventions
- Cobicistat, Darunavir/Cobicistat, Rivaroxaban
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV/AIDS
- Interventions
- Darunavir/Cobicistat, Dolutegravir
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Stanford, California • Aurora, Colorado
- Conditions
- HIV, HIV Infections
- Interventions
- E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- DRV/COBI FDC
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infections, Obesity
- Interventions
- Biktarvy, Symtuza
- Drug
- Lead sponsor
- East Carolina University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Immunodeficiency Virus Type 1, Human
- Interventions
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC, D/C/F/TAF FDC - Matching Placebo, FTC/TDF FDC Matching Placebo, DRV/COBI FDC Matching Placebo
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 725 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- PI, RTV, FTC/TDF, Stribild
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Hayward, California + 28 more
- Conditions
- HIV, HBV
- Interventions
- E/C/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- BMS-663068, Darunavir, Cobicistat
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- HIV-1 Infection
- Interventions
- elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • San Diego, California • Torrance, California + 17 more
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more